MyFinsight
Home
Blog
About
Generate Biomedicines, Inc. (GENB)
Generate Biomedicines, Inc. (GENB)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$58,877K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from sales and maturiti...
Non-cash stock-based compensatio...
Prepaid expenses and other curre...
Others
Negative Cash Flow Breakdown
Net loss
Deferred revenue
Other assets
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
Net loss
-67,255
-61,714
Amortization and accretion on marketable securities
387
146
Non-cash stock-based compensation
8,238
6,395
Non-cash lease expense
2,692
2,094
Depreciation and amortization
3,224
3,273
Changes in fair value of convertible preferred stock warrant liability
0
363
Accounts receivable
0
0
Prepaid expenses and other current assets
-5,911
6,221
Other assets
4,312
-2,045
Accounts payable
-1,954
3,754
Operating lease liabilities
-1,948
-1,841
Other long term liabilities
0
-117
Accrued expenses and other liabilities
4,161
-21,049
Deferred revenue
-6,314
-7,224
Net cash used in operating activities
-57,944
-80,388
Purchase of marketable securities
606
321,153
Purchases of property and equipment
933
3,781
Proceeds from sales and maturities of marketable securities
34,850
65,000
Net cash (used in) provided by investing activities
33,311
-259,934
Proceeds from issuance of convertible preferred stock, net of issuance costs
0
0
Proceeds from issuance of common stock from the initial public offering, net of underwriting discounts, commissions and offering expenses
0
369,289
Contributions from non-controlling interests
0
7,500
Proceeds from exercise of stock options
414
3,217
Payments on finance lease obligations
993
1,115
Net cash provided by financing activities
-579
378,891
Net increase (decrease) in cash, cash equivalents and restricted cash
-25,212
38,569
Cash, cash equivalents and restricted cash at beginning of period
164,607
126,038
Cash, cash equivalents and restricted cash at end of period
139,393
164,607
Cash and cash equivalents, end of period
135,359
-
Restricted cash and cash equivalents (vie)
0
-
Long-term restricted cash
4,034
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from sales and
maturities of marketable...
$34,850K
Net cash (used in)
provided by investing...
$33,311K
Canceled cashflow
$1,539K
Net increase
(decrease) in cash, cash...
-$25,212K
Canceled cashflow
$33,311K
Non-cash stock-based
compensation
$8,238K
Prepaid expenses and
other current assets
-$5,911K
Accrued expenses and
other liabilities
$4,161K
Depreciation and
amortization
$3,224K
Non-cash lease expense
$2,692K
Proceeds from exercise of
stock options
$414K
Purchases of property and
equipment
$933K
Purchase of marketable
securities
$606K
Net cash used in
operating activities
-$57,944K
Canceled cashflow
$24,226K
Net cash provided by
financing activities
-$579K
Canceled cashflow
$414K
Net loss
-$67,255K
Deferred revenue
-$6,314K
Other assets
$4,312K
Accounts payable
-$1,954K
Operating lease
liabilities
-$1,948K
Amortization and accretion on
marketable securities
$387K
Payments on finance lease
obligations
$993K
Buy us a coffee